Repligen Corp (RGEN) stock
RGENNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 30, 2026Score 7/30133% above fair value
$162.18−0.60 (-0.37%)
Close on Nov 17, 2026Market cap $10.37BP/E –Yield –
Repligen EPS
Diluted earnings per share is net income divided by the share count including options and convertible securities.
Repligen's EPS for the twelve months ending Sep 30, 2021 was $2.10, up 156.1% year over year. For fiscal 2025 it was $0.86. Over ten years it grew 11.9% a year on average. The highest annual figure on record is $3.24 in fiscal 2022.
Annual eps
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $0.86 | – |
| FY2024 | Dec 31, 2024 | -$0.46 | -173.0% |
| FY2023 | Dec 31, 2023 | $0.63 | -80.6% |
| FY2022 | Dec 31, 2022 | $3.24 | +44.6% |
| FY2021 | Dec 31, 2021 | $2.24 | +101.8% |
| FY2020 | Dec 31, 2020 | $1.11 | +152.3% |
| FY2019 | Dec 31, 2019 | $0.44 | +18.9% |
| FY2018 | Dec 31, 2018 | $0.37 | -48.6% |
| FY2017 | Dec 31, 2017 | $0.72 | +111.8% |
| FY2016 | Dec 31, 2016 | $0.34 | +21.4% |
| FY2015 | Dec 31, 2015 | $0.28 | +12.0% |
| FY2014 | Dec 31, 2014 | $0.25 | -50.0% |
| FY2013 | Dec 31, 2013 | $0.50 | – |
| FY2011 | Mar 31, 2011 | $0.00 | – |
| FY2010 | Mar 31, 2010 | -$0.13 | – |
Quarterly eps
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$0.68 | -361.5% |
| Q2 FY2026 | Jun 30, 2026 | $0.09 | -10.0% |
| Q1 FY2026 | Mar 31, 2026 | $0.15 | – |
| Q3 FY2025 | Sep 30, 2025 | $0.26 | +160.0% |
| Q2 FY2025 | Jun 30, 2025 | $0.26 | +333.3% |
| Q1 FY2025 | Mar 31, 2025 | $0.10 | -66.7% |
| Q3 FY2024 | Sep 30, 2024 | -$0.01 | -102.9% |
| Q2 FY2024 | Jun 30, 2024 | $0.10 | -63.0% |
| Q1 FY2024 | Mar 31, 2024 | $0.06 | -91.5% |
| Q3 FY2023 | Sep 30, 2023 | $0.30 | -65.9% |
| Q2 FY2023 | Jun 30, 2023 | $0.35 | -56.8% |
| Q1 FY2023 | Mar 31, 2023 | $0.27 | -53.4% |
| Q3 FY2022 | Sep 30, 2022 | $0.71 | +10.9% |
| Q2 FY2022 | Jun 30, 2022 | $0.88 | +69.2% |
| Q1 FY2022 | Mar 31, 2022 | $0.81 | +125.0% |
| Q3 FY2021 | Sep 30, 2021 | $0.58 | +114.8% |
| Q2 FY2021 | Jun 30, 2021 | $0.64 | +113.3% |
| Q1 FY2021 | Mar 31, 2021 | $0.52 | +188.9% |
| Q4 FY2020 | Dec 31, 2020 | $0.36 | +414.3% |
| Q3 FY2020 | Sep 30, 2020 | $0.27 | +800.0% |
| Q2 FY2020 | Jun 30, 2020 | $0.30 | +76.5% |
| Q1 FY2020 | Mar 31, 2020 | $0.18 | +5.9% |
| Q4 FY2019 | Dec 31, 2019 | $0.07 | -41.7% |
| Q3 FY2019 | Sep 30, 2019 | $0.03 | -70.0% |
| Q2 FY2019 | Jun 30, 2019 | $0.17 | +183.3% |
| Q1 FY2019 | Mar 31, 2019 | $0.17 | +112.5% |
| Q4 FY2018 | Dec 31, 2018 | $0.12 | -55.6% |
| Q3 FY2018 | Sep 30, 2018 | $0.10 | -9.1% |
| Q2 FY2018 | Jun 30, 2018 | $0.06 | -75.0% |
| Q1 FY2018 | Mar 31, 2018 | $0.08 | -11.1% |
| Q4 FY2017 | Dec 31, 2017 | $0.27 | +80.0% |
| Q3 FY2017 | Sep 30, 2017 | $0.11 | – |
| Q2 FY2017 | Jun 30, 2017 | $0.24 | – |
| Q1 FY2017 | Mar 31, 2017 | $0.09 | – |
| Q4 FY2016 | Dec 31, 2016 | $0.15 | – |
- Revenue
- Gross Profit
- Operating Income
- Net Income
- EBITDA
- Free Cash Flow
- Operating Cash Flow
- R&D Expenses
- Gross Margin
- Operating Margin
- Profit Margin
- Total Debt
- Cash
- Total Assets
- Shares Outstanding
- Market Cap
- Enterprise Value
- PE Ratio
- Price to Sales Ratio
- Price to Book Ratio
- EV/EBITDA
- Price to Free Cash Flow
- All statistics
See a number that looks wrong?